Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)-Reference-Cited by-同舟云学术

Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024)

Published:2024-07 Issue:1 Volume:212 Page:3-10
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Holzbeierlein Jeffrey¹,Bixler Brooke R.²,Buckley David I.³,Chang Sam S.⁴,Holmes Rebecca S.³,James Andrew C.⁵,Kirkby Erin²,McKiernan James M.⁶,Schuckman Anne⁷

Affiliation:

1. Department of Urology, University of Kansas Cancer Center, Kansas City, Kansas

2. American Urological Association, Linthicum, Maryland

3. Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Portland, Oregon

4. Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee

5. Department of Urology, Texas Urology Group, San Antonio, Texas

6. Department of Urology, Columbia University, New York, New York

7. Department of Urology, University of Southern California, Los Angeles, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Link

http://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003981

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma;New England Journal of Medicine;2024-09-14

2. Topography and Lateralization of Nodal Metastases in Muscle-Invasive Bladder Cancer Using Super-Extended Pelvic Lymph Node Dissection with the Sentinel Lymph Node Technique;Journal of Clinical Medicine;2024-08-29

3. Evaluation of the diagnostic value of YiDiXie™-SS and YiDiXie™ -HS in uroepithelial carcinoma;2024-08-08